Amoéba validates the effectiveness of its biofungicide solution after EFSA approval

Amoéba has reached a crucial milestone with the EFSA approval of its biocontrol active substance. The report confirms the efficacy and low-risk profile of this substance, which is essential for the AXPERA biofungicide innovation developed by Amoéba. This European validation follows the signing of a Memorandum of Understanding with Koppert, the world leader in biocontrol.

EFSA delivered the final conclusions on 13 December 2024, confirming the substance's strengths in terms of efficacy and environmental safety, without requiring maximum residue limits. Amoéba will thus be able to begin approval procedures in several European markets.

The agreement with Koppert aims to facilitate the commercial and industrial deployment of Amoéba. The outlook paints a promising future for the company, anticipating market entry in 2025.